PDF(Pubmed)
Abstract：
Hearing impairment in patients with chronic kidney disease (CKD), can affect the quality of life. At present, hearing dysfunction does not have an approved pharmacologic therapy. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with chronic kidney disease. We conducted a randomized controlled trial of 40 chronic kidney disease patients not on dialysis with hearing impairment. Participants were randomly divided into two groups. One group received curcumin daily and the other received a placebo for 12 weeks. The interval between III and V waves, latency of wave V, auditory brain stem response (ABR) threshold, speech reception threshold (SRT), and speech discrimination score (SDS) were evaluated and analyzed before and after the intervention. After treatment, in the curcumin group, III-V waves interval and the latency of wave V were significantly reduced (P value < 0.0001), also ABR threshold was demonstrated a significant improvement (P value < 0.0001). In the trial group, the SDS was increased (P = 0.001) and the SRT was attenuated (P < 0.0001). We had either significant deterioration due to the course of the disease or insignificant changes in the placebo group. Daily administration of curcumin, can significantly improve hearing impairment in CKD patients. Accordingly, curcumin should be considered as a therapeutic option for treating hearing impairment in patients with chronic kidney disease.
摘要：
慢性肾脏病（CKD）患者的听力障碍，会影响生活质量。目前,听力障碍没有批准的药物治疗。本研究旨在探讨姜黄素对慢性肾脏病患者听力损害的保护作用及其可能机制。我们对40名未接受透析并有听力障碍的慢性肾脏病患者进行了一项随机对照试验。参与者被随机分为两组。一组每天接受姜黄素，另一组接受安慰剂12周。III波和V波之间的间隔，V波的潜伏期,听觉脑干反应（ABR）阈值，语音接收阈值(SRT)，对干预前后的言语歧视评分(SDS)进行评价和分析。治疗后,在姜黄素组中，III-V波间隔和V波潜伏期明显缩短(P值<0.0001),ABR阈值也显著改善(P值<0.0001).在试验组中,SDS增加（P=0.001），SRT减弱（P<0.0001）。在安慰剂组中，我们要么由于病程而明显恶化，要么变化不明显。姜黄素的每日给药，可以明显改善CKD患者的听力障碍。因此，姜黄素应考虑作为治疗慢性肾病患者听力障碍的治疗选择。
